We are pleased to announce that the Manitoba Neuroscience Network will again
be accepting applications for 2018/19 TRAVEL AWARDS FOR NEUROSCIENCE
PROJECTS
A legacy fund created by the estate of Nancy Hettie Clark is used to enrich
neuroscience training and support opportunities to network within the wider
neuroscience community. Two travel awards of up to $700 each are intended to
be awarded annually to a graduate student and a postdoctoral fellow at the
University of Manitoba. The application deadline is MAY 1. The eligible
travel period is between May 1, 2018 and April 30, 2019, BUT all eligible
travel claims must be complete by March 31, 2019.
Eligibility: Eligible trainees are either graduate students or
postdoctoral fellows. Student candidates must be enrolled as full-time
Ph.D. students in the Faculty of Graduate Studies, University of Manitoba,
and have a cumulative graduate grade point average of 3.5 or greater
(University of Manitoba scale). Postdoctoral fellow candidates must be
within the first five years after awarding of their doctoral degree and have
a full-time appointment at the University of Manitoba or an affiliated
hospital or institute. Candidates must demonstrate excellent research
performance and potential in a neurosciences-related discipline, and must
demonstrate they will disseminate research results that reflect a
high-quality contribution by The University of Manitoba.
How to apply: A complete application package consists of the following:
* Cover letter stating the following (1 page maximum):
o Application category (PhD student or postdoctoral fellow) and your start
date in that position
o The conference title, location and dates
o Type of presentation (e.g. poster or oral)
o The importance of the meeting and significance for career development
o Any information that would allow reviewers to assess the significance or
impact of the conference (e.g. abstracts are peer-reviewed)
o Clearly state your graduate GPA (students only)
* Graduate level academic transcript (students only)
* Listing of scholarly output (publications and presentations)
* Support letter from the primary research advisor with (a) a merit
assessment of the candidate and project, and (b) confirmation that there is
a commitment to cover all eligible travel expenses less the award value
* Copy of the submitted abstract
Submit all materials to <mailto:info@manitobaneuroscience.ca>
info(a)manitobaneuroscience.ca by MAY 1. The support letter may be appended or
sent separately by the research advisor.
Good luck!
******************************************
<http://www.manitobaneuroscience.ca/>
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
<https://www.instagram.com/manitobaneuroscience/>
<https://twitter.com/manitobaneuro>
cid:image001.jpg@01D158FE.B69B8D00
Hello everyone,
I received this email from the organizers of the Canadian National Brain Bee. As part of their promotional efforts, they are starting an initiative on Instagram to highlight Canadian neuroscience researchers. If you are interested in participating, the details are provided below.
Best wishes, Sari
Sari S. Hannila, PhD
Director of Outreach, Manitoba Neuroscience Network
cid:image004.jpg@01D158FE.B69B8D00
From: Alex Xue [mailto:xuea1@mcmaster.ca]
Sent: Tuesday, March 20, 2018 5:14 PM
To: everyone(a)brainbee.ca; edmonton(a)brainbee.ca
Cc: Piskuric, Nikol
Subject: Brain Bee Instagram Post: Humans of Neuroscience
Dear Neuroscientist,
My name is Alex, and I am a second year student in the Neuroscience Program at McMaster University. I am also involved in planning and promoting the Canadian National Brain Bee, a neuroscience competition for high school students across Canada. As a member of the Social Media Team, I have helped create an Instagram page (Canada Brain Bee) to increase awareness of the National Bee, to create a community among prospective neuroscience students, and to promote interesting and important Canadian neuroscience research.
I am reaching out to you today to request your participation in our Instagram “Humans of Neuroscience” project, which highlights neuroscience researchers across Canada. Your participation would include briefly answering one or all of the following questions, and providing a picture of yourself (either headshot, or photo of you in your lab).
1. What got you interested in neuroscience?
2. In “layman’s terms”, what is the major focus of your research? Do you have a favourite publication that interested followers should read?
3. Where is the future of neuroscience headed? In your view, what are the remaining “big questions” in neuroscience?
Please forward this email to any Canadian colleagues that may be interested in being featured on our Instagram page. Moreover, feel free to email me if you have any questions or comments. Thank you for your time, and have a great day!
Sincerely,
Alex Xue, on behalf of the Social Media Team
Brain Bee Organizational Committee
Good morning! Students you are invited to a career development workshop on Thursday March 22. See details below and attachments for more info. Contact Stephanie Kereliuk if you have questions: umkereli(a)myumanitoba.ca
Crystal
-------------------------------------------------------------------------------------------
Crystal Acosta
B.Sc., M.Sc., PhD. Student
Pharmacology & Therapeutics
University of Manitoba
St. Boniface Hospital Albrechtsen Research Centre
R2032 - 351 Taché Avenue
Winnipeg, MB, R2H 2A6
Kleysen Institute for Advanced Medicine
SR452 - 710 William Avenue
Winnipeg, MB, R3E 0Z3
P: (204) 997-1985<tel:204%29%20997-1985>
E: umacostc(a)myumanitoba.ca<mailto:umacostc@myumanitoba.ca>
________________________________
From: Stephanie Kereliuk
Sent: Monday, March 19, 2018 10:22 AM
To: Crystal May Acosta; Adam Hogan-Cann
Subject: Fwd: DREAM Seminar Series - Thursday March 22
Hey guys!
On Thursday March 22 the DREAM Trainees will be hosting a career development based seminar with Thermo Fisher representatives Shantel Gushue and Brett Dalman. It will take place from 3-4pm in 500 JBRC (5th floor CHRIM) Pharmacology students and other members of KIAM are invited to attend. Could you please circulate the e-mail below/poster to MNN/neuroscience/KIAM students/any one who would be interested?
Thanks!
Stephanie
Begin forwarded message:
From: DREAM Trainees <dreamtrainees(a)gmail.com<mailto:dreamtrainees@gmail.com>>
Subject: DREAM Seminar Series - Thursday March 22
Date: March 19, 2018 at 10:08:31 AM CDT
To: undisclosed-recipients:;
Hi everyone,
On Thursday March 22 we will have DREAM Seminar Series. As always, it will take place from 3-4pm in 500JBRC and everyone is welcome to attend!
Shantel & Brett from Thermo Fisher Scientific will be here to give us a carrer development based talk and they will present on the skills required to work in sales and how to transition from working in the lab to a sales role. There biographies are included below:
Brett Dalman, BSc. Brett graduated with a Bachelor of Science, Major Microbiology with a minor in zoology in the Co-op Program from the University of Manitoba. During university, she participated in the co-op program gaining experience with Miraculins (a biotech company working on cancer), and the Canadian Food Inspection Agency (CFIA). Upon graduation, she continued to work at the CFIA as a permanent technician working with high containment viruses for research and diagnostics applications. In 2010, she began the next stage in her career and became a Sales Representative, for the distribution company VWR, dealing with a variety of accounts and product lines. In 2014, she was approached to join a more specialized company as a Territory Manager for Thermo Fisher Scientific where she relies on her scientific degree to better support research labs.
Shantel Gushue, MSc. Shantel Gushue graduated with her Bachelor of Science Degree as a ‘Student of Distinction’ from the University of Winnipeg in 2008. Shortly thereafter, she pursued graduate school at the University of Manitoba in the Department of Medical Microbiology and Infectious Disease. After working approximately 10 months as a Clinical Research Coordinator at the Children’s Hospital Research Institute of Manitoba, she landed a position with Fisher Scientific as an Account Manager. Her primary focus is to sell laboratory supplies, chemicals, and equipment into pharmaceutical, clinical, industrial, academic, and agricultural accounts. Although she initially had little experience in the area of sales and business, she has been very successful and continues to drive sales for the company as well as create long lasting partnerships with both colleagues and customers.
The rest of the March Schedule is as follows:
Thursday March 29 - Work in Progress by Dr. Kozeta Miliku (Human milk oligosaccharides, food sensitization and asthma in early childhood) (3-4PM 500JBRC)
If you are interested in presenting a seminar (journal article, update on your work, other topic of interest) please respond to this e-mail. April 5th and May dates are available.
Also please don't forget to forward any updates or items you would like included in the DREAM Trainees Newsletter to this e-mail.
--
Connect with us on Twitter @DREAM_trainees & #DREAMwpg
[https://drive.google.com/uc?id=1m3ak0u_Ks9lTI_wGOxDapSzRjshBH4CL&export=dow…]
cid:image001.jpg@01D158FE.B69B8D00
S E M I N A R & V I S I T I N G S P E A K E R S E R I E S
D AT E
Friday, March 23rd, 2018
9 am
L O C AT I O N
236/238 PsycHealthBldg.
S P E A K E R
<http://umanitoba.ca/faculties/health_sciences/medicine/units/physiology/con
tacts/karimi.html> Dr. Soheila Karimi
Associate Professor
Department of Physiology & Pathophysiology
Senior Scientist, Regenerative Medicine Program
Principal Investigator, Spinal Cord Research Center
T O P I C
Emerging therapeutic targets for spinal cord injury and Multiple Sclerosis
B I O
Dr. Soheila Karimi is an Associate Professor in the Department of Physiology
and Pathophysiology, and the Regenerative Medicine Program, in the Rady
Faculty of Health Sciences, at the University of Manitoba. Soheila has had a
long-term interest in neural repair and regeneration with a focus on
therapeutic development for spinal cord injury and multiple sclerosis. She
received her PhD degree in neurosciences from the University of Saskatchewan
in 2001, and then undertook a postdoctoral fellowship in spinal cord injury
and stem cell research at the University of Toronto and the Toronto Western
Hospital. During her training, Soheila received numerous academic and
research awards including a Synthes Award from the American Association of
Neurological Surgeons, and postdoctoral fellowships from the Canadian
Institutes of Health Research, Ontario Neurotrauma Foundation and the Heart
and Stroke Foundation. Her postdoctoral work broke a new ground in spinal
cord injury therapeutics by showing that transplantation of neural stem
cells can be used therapeutically to promote myelin repair with improved
recovery of function in preclinical models. Her seminal work has been
instrumental for implementing neural stem cell therapies in human clinical
trials that are currently under way. Soheila joined the University of
Manitoba in 2010 to help in establishing the Regenerative Medicine Program
in Manitoba. Current research in Karimis laboratory focuses on uncovering
disease mechanisms and developing regenerative therapies for spinal cord
injury and multiple sclerosis. Using drug delivery, stem cell therapy,
genetic manipulations and bioengineering approaches, Karimis team have
discovered novel targets that play major roles in regulating cell
replacement and myelin repair in these conditions. Karimis team have
published their discoveries in top-tier journals such as Stem Cells, Nature,
J. Neuroscience, GLIA, J. Neuroinflammation. Karimis research program has
been supported by concurrent grants from the CIHR, Multiple Sclerosis
Society of Canada, NSERC, Canada Foundation for Innovation, Craig H. Neilsen
Foundation in the US, Research Manitoba and the Canadian Paraplegic
Association.
L E A R N I N G O B J E C T I V E S
- Provide an overview on neuroinflammation and demyelination, two
common mechanisms of spinal cord injury (SCI) and multiple sclerosis (MS).
- Discuss novel endogenous regulators of immune response in the
injured and diseased spinal cord
- Highlight our recent advances in therapeutic development for
augmenting oligodendrocyte replacement and myelin repair in CNS
demyelination
/sent on behalf of
Dr. Eftekhar Eftekharpour
Coordinator, Seminar & Visiting Speaker Series
Manitoba Neuroscience Network
E: Eftekhar.Eftekharpour(a)umanitoba.ca
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480
cid:image001.jpg@01D158FE.B69B8D00
/sent on behalf of Dr. Ben Albensi
Everyone is invited to attend.
Dementia Journal Club
Date: March 20th, 2018
Time: 12 Noon
Location: St Boniface Hosp. Res. R1003, 351 Tache Ave, Wpg.
Dr. Phil St. John <http://umanitoba.ca/centres/aging/people/130.html>
Associate Professor
Co-lead Manitoba site investigator, CLSA
Section of Geriatrics, Department of Internal Medicine, Max Rady College of
Medicine, Rady Faculty of Health Sciences;
cross appointment, Department of Family Medicine, Max Rady College of
Medicine, Rady Faculty of Health Sciences
Effect of a 24-Month Physical Activity Intervention vs Health Education on
Cognitive Outcomes in Sedentary Older Adults The LIFE Randomized Trial
Physical activity, cognitive decline, and risk of dementia: 28 year
follow-up of Whitehall II cohort study
With kind regards,
Ben
Benedict C. Albensi, PhD, BCMAS, CRQM
Professor & Manitoba Dementia Research Chair
Max Rady College of Medicine
cid:image001.png@01D3B158.2C68F230
Dept. of Pharmacology & Therapeutics
Biomedical Engineering Core Member
Faculties of Health Sciences, Engineering, & Science
Research Affiliate, Centre on Aging
Principal Investigator, St. Boniface Hospital Research
Everett Endowment Fund Chair
Division of Neurodegenerative Disorders (DND)
cid:image003.png@01D1B033.4251C1D0
St. Boniface Hospital Research
351 Tache Ave./Lab 4050 Winnipeg, Manitoba R2H 2A6 Canada
Tel: 204-235-3942 (office) Tel: 204-235-3941 (lab)
Email: balbensi(a)sbrc.ca
Gentle reminder .today .
cid:image001.jpg@01D158FE.B69B8D00
SPECIAL LECTURE:
B R A I N A W A R E N E S S W E E K
D A T E
Thursday, March 15th, 2018
12Noon
*Followed by a Trainee Lunch in Rm 636 BMSB
L O C A T I O N
Rm 626 Basic Sci Bldg.
S P E A K E R
D R . K A R I M F O UA D
C A N A D A R E S E A R C H C H A I R
S P I N A L C O R D I N J U R Y
T O P I C
Promoting plasticity and recovery following spinal cord injury
Karim Fouad studied Biology in Germany where he also performed his Graduate
studies on motor control of invertebrates. During his time as PDF in
Edmonton, with Dr. Pearson he switched to locomotor control in vertebrates,
which triggered his interest in neuroplasticity. He expanded his research
in the area of injury induced neuroplasticity in the groups of Drs. Schwab
and Dietz in Zürich, Switzerland, especially in relation to spinal cord
injuries. In 2001 he started his group in at the University of Alberta in
Edmonton, where he is now a Professor and Canada Research Chair in the
Department of Physical Therapy, in the Faculty of Rehabilitation Medicine.
Karim Fouads research focuses on repair of the injured spinal cord. This
includes combined treatment approaches to regenerate lost connections but
also to rewire spared circuitry.
He uses rehabilitative training to study, and enhance mechanisms of neuro
plasticity, but also as a tool to promote functional recovery when
plasticity is pharmacologically enhanced. Over the last years he developed a
more compressive view on plasticity exploring a wide range of changes that
occur after spinal injuries, ranging from spasticity, to blood flow and
mental health.
/sent on behalf of
Dr. Eftekhar Eftekharpour
Coordinator, Seminar & Visiting Speaker Series
Manitoba Neuroscience Network
E: Eftekhar.Eftekharpour(a)umanitoba.ca
Kelly Jorundson
Coordinator, Membership & Operations
Manitoba Neuroscience Network
Email: kjorund(a)sbrc.ca
Tel: 204.235.3939
Fax: 204.237.4092
St. Boniface Hospital Albrechtsen Research Centre
Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA
This email and any attachments may contain confidential, personal and/or
privileged information intended for a specific individual and purpose. If
you are not the intended recipient, you are hereby notified that any
disclosure, copying, retaining, distribution, access, use or modification of
the contents of this e-mailed information is strictly prohibited. If you
receive this communication in error, please notify the sender immediately
and delete or destroy the email message and any attachments or copies.
******************************************
<http://www.manitobaneuroscience.ca/> cid:image003.jpg@01D159B3.9F0B9710
<https://www.facebook.com/manitobaneuroscience/?fref=ts>
cid:image007.png@01D29326.7E26D480
<https://www.instagram.com/manitobaneuroscience/>
cid:image009.jpg@01D29326.7E26D480 <https://twitter.com/manitobaneuro>
cid:image010.png@01D29326.7E26D480
[cid:image001.jpg@01D158FE.B69B8D00]
B R A I N A W A R E N E S S W E E K
SPECIAL EVENT:
D A T E
Wednesday, March 14th, 2018
7:00pm
L O C A T I O N
McNally Robinson Bookstore
4000-1120 Grant Avenue
IN CONVERSATION WITH DR. PIERRE MARQUET
C A N A D A EXCELLENCE R E S E A R C H C H A I R
NEUROPHOTONICS
T O P I C
Identification of a childhood risk syndrome of major psychiatric diseases: a step towards their prevention.
Psychiatrist, Pierre Marquet also holds a Master of physical engineering from Ecole Polytechnique Fédérale de Lausanne, Switzerland and an M.D./Ph.D. in neurophotonics from University of Lausanne. Recognized worldwide for his pioneering work on digital holographic microscopy, he is a professor of psychiatry at Université Laval and the chairholder of the CERC in Neurophotonics. He is also the director of the International Joint Research Unit (IJRU) in neurodevelopment and child psychiatry. The goal of this IJRU is to identify new risk biomarkers and endophenotypes to define childhood risk syndromes of major psychiatric disorders including schizophrenia, bipolar disorders and major depression disorder with the help of neurophotonics tools. He is the author or co-author of more than 140 scientific publications (6500 citations, h-index 36), of many patents and is the co-founder of three technological start-up companies.
Kae Normandeau
Administrative Manager
Neuroscience Research Program
SR440 KIAM Building
P: 204-318-2569
E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca>
This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies.
******************************************
[cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/>
[cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>
[cid:image001.jpg@01D158FE.B69B8D00]
SPECIAL LECTURE:
B R A I N A W A R E N E S S W E E K
D A T E
Wednesday, March 14th, 2018
12Noon
*Followed by a Trainee Lunch in SR415, KIAM
L O C A T I O N
Theatre C, BMSB
S P E A K E R
D R . PIERRE MARQUET
C A N A D A EXCELLENCE R E S E A R C H C H A I R
NEUROPHOTONICS
T O P I C
Neurophotonics to Intercept the Emergence of Major Psychiatric Disorders
Major psychiatric disorders (MPDs) including psychosis and mood disorders affect *4% of the population. MPDs have chronic courses since their diagnoses, solely based on clinical symptoms, are very late and thus better treatments are only palliative. The successful development of early treatment and primary prevention is largely impeded by the lack of reliable risk biomarkers or endophenotypes (B/Es). This is a critical issue since MPDs have a neurodevelopmental origin and early intervention can improve outcomes.
>From a developmental standpoint, the identification of B/Es in patients with MPDs and in their offspring at genetic risk will play a pivotal role in the definition of childhood risk syndromes and their corresponding abnormal trajectories. This approach is particularly relevant given that high-risk children carry many of the indicators of brain dysfunctions that adult patients have.
Within this framework, I will present how the development of new multimodal optical imaging techniques in combination with stem cell technologies, including human induced pluripotent stem cells approaches, can contribute to identifying new cellular B/Es relevant both to define childhood risk syndromes and to determine cellular processes likely to be involved in the pathogenesis of these MPDs.
Kae Normandeau
Administrative Manager
Neuroscience Research Program
SR440 KIAM Building
P: 204-318-2569
E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca>
This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies.
******************************************
[cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/>
[cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>
[cid:image001.jpg@01D158FE.B69B8D00]
B R A I N A W A R E N E S S W E E K
SPECIAL EVENT:
D A T E
Wednesday, March 14th, 2018
7:00pm
L O C A T I O N
McNally Robinson Bookstore
4000-1120 Grant Avenue
IN CONVERSATION WITH DR. PIERRE MARQUET
C A N A D A EXCELLENCE R E S E A R C H C H A I R
NEUROPHOTONICS
T O P I C
Identification of a childhood risk syndrome of major psychiatric diseases: a step towards their prevention.
Psychiatrist, Pierre Marquet also holds a Master of physical engineering from Ecole Polytechnique Fédérale de Lausanne, Switzerland and an M.D./Ph.D. in neurophotonics from University of Lausanne. Recognized worldwide for his pioneering work on digital holographic microscopy, he is a professor of psychiatry at Université Laval and the chairholder of the CERC in Neurophotonics. He is also the director of the International Joint Research Unit (IJRU) in neurodevelopment and child psychiatry. The goal of this IJRU is to identify new risk biomarkers and endophenotypes to define childhood risk syndromes of major psychiatric disorders including schizophrenia, bipolar disorders and major depression disorder with the help of neurophotonics tools. He is the author or co-author of more than 140 scientific publications (6500 citations, h-index 36), of many patents and is the co-founder of three technological start-up companies.
Kae Normandeau
Administrative Manager
Neuroscience Research Program
SR440 KIAM Building
P: 204-318-2569
E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca>
This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies.
******************************************
[cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/>
[cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>
[cid:image001.jpg@01D158FE.B69B8D00]
SPECIAL LECTURE:
B R A I N A W A R E N E S S W E E K
D A T E
Wednesday, March 14th, 2018
12Noon
*Followed by a Trainee Lunch in SR415, KIAM
L O C A T I O N
Theatre C, BMSB
S P E A K E R
D R . PIERRE MARQUET
C A N A D A EXCELLENCE R E S E A R C H C H A I R
NEUROPHOTONICS
T O P I C
Neurophotonics to Intercept the Emergence of Major Psychiatric Disorders
Major psychiatric disorders (MPDs) including psychosis and mood disorders affect *4% of the population. MPDs have chronic courses since their diagnoses, solely based on clinical symptoms, are very late and thus better treatments are only palliative. The successful development of early treatment and primary prevention is largely impeded by the lack of reliable risk biomarkers or endophenotypes (B/Es). This is a critical issue since MPDs have a neurodevelopmental origin and early intervention can improve outcomes.
>From a developmental standpoint, the identification of B/Es in patients with MPDs and in their offspring at genetic risk will play a pivotal role in the definition of childhood risk syndromes and their corresponding abnormal trajectories. This approach is particularly relevant given that high-risk children carry many of the indicators of brain dysfunctions that adult patients have.
Within this framework, I will present how the development of new multimodal optical imaging techniques in combination with stem cell technologies, including human induced pluripotent stem cells approaches, can contribute to identifying new cellular B/Es relevant both to define childhood risk syndromes and to determine cellular processes likely to be involved in the pathogenesis of these MPDs.
Kae Normandeau
Administrative Manager
Neuroscience Research Program
SR440 KIAM Building
P: 204-318-2569
E: kae.normandeau(a)umanitoba.ca<mailto:kae.normandeau@umanitoba.ca>
This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies.
******************************************
[cid:image003.jpg@01D159B3.9F0B9710]<http://www.manitobaneuroscience.ca/>
[cid:image007.png@01D29326.7E26D480]<https://www.facebook.com/manitobaneuroscience/?fref=ts> [cid:image009.jpg@01D29326.7E26D480] <https://www.instagram.com/manitobaneuroscience/> [cid:image010.png@01D29326.7E26D480] <https://twitter.com/manitobaneuro>